# US Thrombus Treatment Market > US Thrombus Treatment Market Research Report By Type (Atrial Thrombus, Venous Thrombus) and By Treatment (Medical Therapy, Surgery, Others) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 6.95% - **2024:** $ 9.16 Billion - **2025:** $ 9.8 Billion - **2035:** $ 19.18 Billion - **Key Players:** Bayer AG (DE), Bristol-Myers Squibb Company (US), Johnson & Johnson (US), Roche Holding AG (CH), Sanofi S.A. (FR), AstraZeneca PLC (GB), Pfizer Inc. (US), Merck & Co., Inc. (US) **Report ID:** MRFR/HC/11918-HCR · **Pages:** 100 · **Author:** Vikita Thakur & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-thrombus-treatment-market-13443 --- ## Market Summary ## **US Thrombus Treatment Market Overview** As per MRFR analysis, the US Thrombus Treatment Market Size was estimated at 8.97 (USD Billion) in 2023. The US Thrombus Treatment Market Industry is expected to grow from 9.5(USD Billion) in 2024 to 22 (USD Billion) by 2035. The US Thrombus Treatment Market CAGR (growth rate) is expected to be around 7.933% during the forecast period (2025 - 2035). ### **Key US Thrombus Treatment Market Trends Highlighted** The US Thrombus Treatment Market is witnessing significant trends reflecting a growing focus on innovative therapies and technologies. Key market drivers include the rising prevalence of thromboembolic disorders, particularly among the aging population in the US, where about 46 million residents are over 65 years old. This age group is experiencing increased occurrences of conditions such as deep vein thrombosis and pulmonary embolism. Moreover, advancements in medical technology, such as the development of catheter-based interventions and mechanical thrombectomy devices, are enhancing treatment outcomes and patient safety. Opportunities to be explored in this market include the potential for growth in outpatient treatment options, as healthcare providers increasingly seek to reduce hospital stays and associated costs. This shift also encourages the development of specialized [thrombus treatments](../../../reports/thrombus-treatment-market-11453) that can be administered in less invasive settings. Additionally, there is an opportunity for improving patient education on thrombus prevention and treatment, as many patients are still not fully aware of their risks or treatment options. Trends in recent times show a stronger emphasis on personalized medicine and the integration of artificial intelligence in treatment plans. Healthcare professionals in the US are increasingly relying on data-driven decisions for thrombus management, which enhances both efficacy and efficiency in treatment strategies. Moreover, there is a growing collaboration between biotech firms and medical institutions aimed at accelerating research and development of novel thrombolytic agents. These trends collectively suggest a rapidly evolving landscape in the US Thrombus Treatment Market, with a focus on improving patient outcomes and operational efficiencies in healthcare delivery. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **US Thrombus Treatment Market Drivers** #### **Increasing Incidence of Cardiovascular Diseases** The rising prevalence of cardiovascular diseases, particularly in the United States, is a significant driver of the US Thrombus Treatment Market Industry. According to the Centers for Disease Control and Prevention (CDC), nearly 697,000 Americans die from heart disease every year, accounting for one in every five deaths. This alarming statistic underscores a growing patient base that necessitates effective thrombus treatment options. As healthcare providers and institutions respond to this urgent need, organizations such as the American Heart Association are actively investing in research initiatives aimed at improved thrombus management. Furthermore, advancements in thrombolytic therapies and anticoagulants are evolving concurrently with the increase in patient numbers, ensuring that the industry aligns closely with treatment needs. This continual rise in cardiovascular problems guarantees a sustained demand for thrombus treatment solutions, stimulating market growth well into the next decade. #### **Technological Advancements in Medical Devices** The US Thrombus Treatment Market Industry is experiencing a surge in growth due to rapid advancements in medical technologies related to thrombus treatment. Innovative solutions such as catheter-directed thrombolysis and mechanical thrombectomy are becoming more prevalent in medical practices. The FDA has reported an increase in the approval of new devices specializing in thrombus management, with over 30 new products gaining approval in the last five years. Companies like Boston Scientific and Medtronic are leading the charge with their cutting-edge technologies that enhance the efficiency and effectiveness of thrombus treatments. As these devices enter the market and prove their efficacy in clinical settings, healthcare providers are more inclined to adopt these innovations, further propelling market growth. #### **Rising Geriatric Population** The aging population in the United States is a compelling driver for the US Thrombus Treatment Market Industry. By 2030, the number of Americans aged 65 and older is projected to reach approximately 73 million, which represents roughly 20% of the total population according to the U.S. Census Bureau. This demographic shift is associated with an increased incidence of thrombotic diseases, as older adults are at a higher risk of stroke and other cardiovascular complications. Organizations such as the American Geriatrics Society emphasize the need for specialized treatments tailored for the elderly, opening new avenues for market expansion. Consequently, pharmaceutical companies and medical device manufacturers are increasingly focused on developing targeted therapies aimed at this vulnerable age group, thereby driving demand for thrombus treatments. #### **Growing Awareness and Education on Thrombosis** Increasing awareness and education regarding thrombosis and its associated health risks have significantly impacted the US Thrombus Treatment Market Industry. Public health campaigns led by agencies like the CDC and the National Blood Clot Alliance (NBCA) have played a pivotal role in educating the public about the risks of thrombus formation and the importance of early diagnosis and treatment. As a result, there has been a notable increase in screening and consultation rates among at-risk populations. Reports indicate that proactive measures have contributed to a 20% growth in diagnoses related to thrombotic conditions over the past five years. This heightened awareness not only drives demand for thrombus treatment options but also encourages investment in Research and Development aimed at advanced therapies, further bolstering market growth. ### **US Thrombus Treatment Market Segment Insights** #### **Thrombus Treatment Market Type Insights** The US Thrombus Treatment Market encompasses various types of thrombus formations, particularly Atrial Thrombus and Venous Thrombus, both of which demonstrate significant importance in terms of prevalence and treatment intervention. Atrial Thrombus typically forms in the heart's atria and is often associated with conditions such as atrial fibrillation, significantly raising the risk of strokes among affected patients. The complexity of the management of Atrial Thrombus due to its relationship with heart health indicates a substantial demand for effective therapeutic solutions in the market. In terms of prevalence, Atrial Thrombus cases are prevalent, especially among the aging population, leading to innovations in treatment methodologies and increased Research and Development activities. On the other hand, Venous Thrombus is predominantly associated with deep vein thrombosis (DVT) and pulmonary embolism (PE). With lifestyle factors such as prolonged inactivity, obesity, and certain genetic predispositions on the rise, the incidence of Venous Thrombus has also seen an upward trend. Effective management of Venous Thrombus is crucial because of the potential complications it poses, including life-threatening conditions like pulmonary embolism. This type is often characterized by clot formation in the venous system, presenting unique treatment challenges that necessitate targeted therapies. The rising awareness surrounding lifestyle-induced health issues further emphasizes the need for improvements in the treatment options available for Venous Thrombus. Overall, both Atrial and Venous Thrombus segments play critical roles in the US Thrombus Treatment Market, each driving demand for innovative therapeutic approaches and contributing significantly to clinical outcomes for patients. Additionally, the increasing healthcare focus on cardiovascular and venous diseases positively influences the market growth, highlighting a clear opportunity for stakeholders invested in the development of advanced treatment modalities. The implications of patient quality of life improvements due to effective thrombus treatment strategies underscore the significance of these segments within the broader context of thrombus healthcare management in the United States. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review #### **Thrombus Treatment Market Treatment Insights** The US Thrombus Treatment Market, particularly within the Treatment segment, exhibits substantial growth potential driven by advancements in technology and increasing awareness of thrombotic disorders. Within this segment, Medical Therapy is crucial as it often represents the first line of defense for many patients, allowing for non-invasive management of thrombus-related conditions. Surgical options also play a significant role, particularly in severe cases where immediate intervention is required. These surgical methods are vital as they not only alleviate symptoms but also prevent further health complications, showcasing the importance of timely medical intervention. The presence of alternative treatments, categorized as Others, contributes diversity to the market, offering insurance to patients seeking various pathways for treatment based on individual needs. Overall, the US Thrombus Treatment Market’s segmentation reflects a strong emphasis on effective, patient-centric approaches that meet the rising demand for diverse and innovative treatment solutions. Factors such as an aging population, lifestyle changes, and rising incidences of associated conditions are expected to drive further advancements and opportunities within this market landscape. Additionally, rising healthcare expenditures and improved healthcare infrastructure in the US are likely to support the growth of these treatment avenues. ### **US Thrombus Treatment Market Key Players and Competitive Insights** The US Thrombus Treatment Market is characterized by a dynamic competitive landscape featuring various players striving to innovate and enhance their therapeutic offerings. This market has witnessed significant growth driven by the increasing prevalence of thrombotic conditions, rising awareness about early diagnosis and treatment options, and advancements in medical technology. During the past few years, companies in this sector have prioritized the development of novel therapies and medical devices to improve patient outcomes and facilitate minimally invasive procedures. The competitive environment is shaped by factors such as product efficacy, safety profiles, regulatory approvals, and the ability to address unmet medical needs, resulting in a race for market share among established firms and emerging players. Teleflex has established a robust presence in the US Thrombus Treatment Market with its diverse portfolio of medical devices that target various thrombotic conditions. The company is well-known for its innovative solutions that cater to the specific needs of healthcare professionals, providing them with effective tools for thrombus management. Teleflex's strengths lie in its commitment to research and development, allowing it to frequently introduce cutting-edge technologies and improve existing products. Additionally, the company has built strategic partnerships to enhance its distribution channels, enabling it to reach a wider audience and solidify its foothold within the market. This strong focus on innovation and a dedicated approach to addressing the challenges faced by healthcare providers contribute to Teleflex's competitive advantage in the thrombus treatment space. Aptus Health has made notable strides in the US Thrombus Treatment Market by offering an array of services and solutions tailored towards improving patient care and outcomes related to thrombotic conditions. Its emphasis on patient-centric approaches has led to the development of key products and services that facilitate informed decision-making within healthcare environments. Aptus Health's strengths lie in its comprehensive data analytics capabilities, which enable healthcare providers to access valuable insights regarding thrombosis management. The company has also engaged in strategic mergers and acquisitions to enhance its market capabilities and broaden its service offerings in the American region. This adaptability and strategic positioning in the US market allow Aptus Health to maintain a competitive edge while providing innovative solutions that address the evolving needs of healthcare professionals and patients. ### **Key Companies in the US Thrombus Treatment Market Include** ### **US Thrombus Treatment Market Industry Developments** The US [Thrombus Treatment Market](../../../reports/thrombus-treatment-market-11453) has witnessed significant developments recently, with various companies making strides in innovation and collaborations. Teleflex has been advancing its catheter-based technologies to enhance thrombus removal procedures, while Boston Scientific is focusing on expanding its thrombectomy devices portfolio. Inari Medical has gained attention for its innovative approach to treating venous thromboembolism, contributing to an increased market presence. Medtronic and Abbott Laboratories continue to invest in Research and Development to improve their product offerings and enhance patient outcomes. In terms of mergers and acquisitions, Medtronic announced its acquisition of Mazor Robotics in December 2020, expanding its capabilities in surgical robotics, which will indirectly benefit the thrombus treatment segment. In another significant move, Teleflex announced its acquisition of the vascular products business from FUJIFILM, which was completed in May 2022, enhancing their product range and market share. Overall, the growth of these companies reflects a growing demand for effective thrombus treatments in the US, driven by rising incidences of thrombotic conditions and an aging population. The focus on technological advancement and strategic acquisitions indicates a robust outlook for the US Thrombus Treatment Market. ### **US Thrombus Treatment Market Segmentation Insights** #### **Thrombus Treatment Market Type Outlook** - Atrial Thrombus - Venous Thrombus #### **Thrombus Treatment Market Treatment Outlook** - Medical Therapy - Surgery - Others ## Market Drivers ### Growing Geriatric Population The aging population in the US is a significant driver of the thrombus treatment market. As individuals age, the risk of thrombus-related conditions increases, necessitating effective treatment options. By 2030, it is estimated that around 20% of the US population will be aged 65 and older, a demographic that is particularly susceptible to thromboembolic events. This demographic shift is likely to create a higher demand for thrombus management solutions, prompting healthcare providers to focus on developing targeted therapies for older patients. Consequently, the thrombus treatment market is expected to grow in response to the needs of this expanding population segment. ### Increased Healthcare Expenditure The thrombus treatment market is benefiting from the rising healthcare expenditure in the US. With healthcare spending projected to reach approximately $6 trillion by 2027, there is a growing allocation of funds towards advanced medical treatments and technologies. This increase in expenditure is likely to enhance access to thrombus treatment options, including novel anticoagulants and minimally invasive procedures. Furthermore, as healthcare policies evolve to support innovative therapies, the thrombus treatment market is expected to expand, providing patients with more effective and accessible treatment alternatives. ### Advancements in Diagnostic Technologies The thrombus treatment market is significantly influenced by advancements in diagnostic technologies. Enhanced imaging techniques, such as CT angiography and ultrasound, allow for earlier and more accurate detection of thrombus formation. This early detection is crucial for timely intervention, which can drastically improve patient outcomes. The integration of artificial intelligence in diagnostic tools is also gaining traction, potentially increasing the efficiency of thrombus identification. As these technologies become more widely adopted, they are expected to facilitate better treatment planning and management, thereby propelling the growth of the thrombus treatment market in the US. ### Regulatory Support for Innovative Therapies The thrombus treatment market is positively impacted by regulatory support for innovative therapies. The US Food and Drug Administration (FDA) has been actively streamlining the approval process for new anticoagulants and thrombectomy devices, encouraging the development of novel treatment options. This regulatory environment fosters innovation and allows for quicker access to advanced therapies for patients. As a result, the thrombus treatment market is likely to see an influx of new products that can address unmet medical needs, ultimately improving patient care and outcomes. ### Rising Incidence of Cardiovascular Diseases The thrombus treatment market is experiencing growth due to the increasing prevalence of cardiovascular diseases in the US. Conditions such as atrial fibrillation and deep vein thrombosis are becoming more common, leading to a higher demand for effective thrombus management solutions. According to recent statistics, cardiovascular diseases account for approximately 697,000 deaths annually in the US, highlighting the urgent need for innovative treatment options. This rising incidence is likely to drive investments in research and development, as healthcare providers seek to improve patient outcomes. Consequently, the thrombus treatment market is poised for expansion as new therapies and technologies emerge to address these pressing health challenges. ## Future Outlook The [Thrombus Treatment Market](https://www.marketresearchfuture.com/reports/thrombus-treatment-market-11453) is projected to grow at a 6.95% CAGR from 2025 to 2035, driven by technological advancements, increasing prevalence of thrombotic disorders, and enhanced healthcare access. **New opportunities:** - Development of AI-driven diagnostic tools for early thrombus detection. - Expansion of telehealth services for remote thrombus management. - Investment in biodegradable stents for improved patient outcomes. By 2035, the thrombus treatment market is expected to achieve substantial growth, reflecting evolving healthcare needs. ## Segment Insights ### By Type: Atrial Thrombus (Largest) vs. Venous Thrombus (Fastest-Growing) In the US thrombus treatment market, the segment distribution shows that atrial thrombus treatments command the largest share, being a well-established segment with significant clinical recognition. In contrast, venous thrombus treatments are gaining traction rapidly, benefitting from advancements in technology and increased awareness of venous conditions, indicating a shift in market dynamics. The growth trends reveal that the atrial thrombus segment continues to dominate due to its established treatment protocols and a larger patient population. Meanwhile, the venous thrombus segment is emerging as the fastest-growing area, driven by innovative treatment options, a greater emphasis on prevention strategies, and evolving patient demographics that highlight the importance of addressing venous thromboembolism. Atrial Thrombus (Dominant) vs. Venous Thrombus (Emerging) Atrial thrombus treatments are characterized by well-established protocols targeting a significant patient population, primarily those at risk of stroke due to atrial fibrillation. The dominance of this segment is supported by effective therapy options such as anticoagulants and catheter-based interventions. On the other hand, venous thrombus treatments are currently seen as an emerging segment, propelled by innovative approaches and increased awareness around deep vein thrombosis (DVT) and pulmonary embolism (PE). This segment is attracting investment and research focus, leading to enhanced therapeutic options and a growing treatment landscape, making it critical for market players to adapt and innovate. ### By Treatment: Medical Therapy (Largest) vs. Surgery (Fastest-Growing) In the US thrombus treatment market, the Medical Therapy segment currently holds the largest share, representing a significant portion of the overall market. This dominance can be attributed to the increasing adoption of anticoagulants and thrombolytics, which are standard treatments for thrombus disorders. The Surgery segment, while smaller in comparison, is rapidly gaining traction, fueled by advancements in surgical techniques and technology, thus contributing to its growth. The growth trends within the Treatment segment show a clear inclination towards less invasive treatment options. The increasing aging population and the prevalence of lifestyle-related diseases have driven a demand for effective thrombus treatments. Additionally, the rise in healthcare expenditure has facilitated access to more advanced therapeutic options, promising a robust market growth in the future. Innovations in drug development and surgical procedures are likely to further bolster both Medical Therapy and Surgery segments. Medical Therapy (Dominant) vs. Surgery (Emerging) Medical Therapy stands as the dominant force in the Treatment segment, characterized by a wide array of anticoagulant and thrombolytic therapies. This dominance is reinforced by patient preference for non-invasive options and the effectiveness of these medications in managing and preventing thrombus formation. Conversely, the Surgery segment is emerging rapidly, reflecting a growing acceptance of surgical interventions for more complex cases. Surgical methods are continually evolving with technical advancements, presenting effective solutions for patients who may not respond to medical therapy alone. Both segments are integral to a comprehensive thrombus management strategy, offering tailored solutions based on individual patient needs. ## Competitive Benchmarking The thrombus treatment market is characterized by a dynamic competitive landscape, driven by increasing prevalence of thromboembolic disorders and advancements in therapeutic options. Key players such as Bayer AG (DE), Bristol-Myers Squibb Company (US), and Johnson & Johnson (US) are strategically positioned to leverage innovation and partnerships to enhance their market presence. Bayer AG (DE) focuses on expanding its portfolio through research and development, while Bristol-Myers Squibb Company (US) emphasizes strategic collaborations to enhance its therapeutic offerings. Johnson & Johnson (US) is actively pursuing digital transformation initiatives to streamline operations and improve patient outcomes. Collectively, these strategies contribute to a competitive environment that is increasingly focused on innovation and patient-centric solutions.In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The market structure appears moderately fragmented, with several key players exerting influence over various segments. This fragmentation allows for diverse therapeutic options, yet the collective strength of major companies shapes the competitive dynamics significantly. In October Bayer AG (DE) announced a partnership with a leading technology firm to integrate AI-driven analytics into its thrombus treatment development processes. This strategic move is likely to enhance Bayer's ability to identify patient needs and tailor therapies accordingly, positioning the company at the forefront of innovation in the market. The integration of AI could streamline research timelines and improve the efficacy of new treatments. In September Bristol-Myers Squibb Company (US) launched a new clinical trial aimed at evaluating the efficacy of its latest anticoagulant therapy. This initiative underscores the company's commitment to advancing treatment options for patients with thromboembolic disorders. By investing in clinical research, Bristol-Myers Squibb is not only enhancing its product pipeline but also reinforcing its reputation as a leader in the thrombus treatment space. In August Johnson & Johnson (US) unveiled a digital health platform designed to support patients undergoing thrombus treatment. This platform aims to provide personalized care and real-time monitoring, reflecting the company's focus on digital transformation. By leveraging technology to enhance patient engagement, Johnson & Johnson is likely to improve treatment adherence and outcomes, thereby solidifying its competitive position. As of November current trends in the thrombus treatment market include a pronounced shift towards digitalization, sustainability, and the integration of AI technologies. Strategic alliances are increasingly shaping the landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is expected to evolve, with a greater emphasis on innovation and technology rather than solely on price. The reliability of supply chains will also play a crucial role in determining market leadership, as companies strive to meet the growing demand for effective thrombus treatments. ## Recent News & Developments The US [Thrombus Treatment Market](../../../reports/thrombus-treatment-market-11453) has witnessed significant developments recently, with various companies making strides in innovation and collaborations. Teleflex has been advancing its catheter-based technologies to enhance thrombus removal procedures, while Boston Scientific is focusing on expanding its thrombectomy devices portfolio. Inari Medical has gained attention for its innovative approach to treating venous thromboembolism, contributing to an increased market presence. Medtronic and Abbott Laboratories continue to invest in Research and Development to improve their product offerings and enhance patient outcomes. In terms of mergers and acquisitions, Medtronic announced its acquisition of Mazor Robotics in December 2020, expanding its capabilities in surgical robotics, which will indirectly benefit the thrombus treatment segment. In another significant move, Teleflex announced its acquisition of the vascular products business from FUJIFILM, which was completed in May 2022, enhancing their product range and market share. Overall, the growth of these companies reflects a growing demand for effective thrombus treatments in the US, driven by rising incidences of thrombotic conditions and an aging population. The focus on technological advancement and strategic acquisitions indicates a robust outlook for the US Thrombus Treatment Market. ## Report Scope | MARKET SIZE 2024 | 9.16(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 9.8(USD Billion) | | MARKET SIZE 2035 | 19.18(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.95% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Bayer AG (DE), Bristol-Myers Squibb Company (US), Johnson & Johnson (US), Roche Holding AG (CH), Sanofi S.A. (FR), AstraZeneca PLC (GB), Pfizer Inc. (US), Merck & Co., Inc. (US) | | Segments Covered | Type, Treatment | | Key Market Opportunities | Advancements in minimally invasive techniques enhance patient outcomes in the thrombus treatment market. | | Key Market Dynamics | Technological advancements and regulatory changes drive innovation in thrombus treatment options and competitive market dynamics. | | Countries Covered | US | ## Frequently Asked Questions **Q: What was the market valuation of the US thrombus treatment market in 2024?** A: The market valuation was $9.16 Billion in 2024. **Q: What is the projected market valuation for the US thrombus treatment market by 2035?** A: The projected valuation for 2035 is $19.18 Billion. **Q: What is the expected CAGR for the US thrombus treatment market during the forecast period 2025 - 2035?** A: The expected CAGR is 6.95% during the forecast period 2025 - 2035. **Q: Which segments are included in the US thrombus treatment market?** A: The segments include Atrial Thrombus, Venous Thrombus, Medical Therapy, Surgery, and Others. **Q: What were the valuations for Atrial Thrombus and Venous Thrombus in 2024?** A: Atrial Thrombus was valued at $3.66 Billion, while Venous Thrombus was valued at $5.5 Billion in 2024. **Q: What are the projected valuations for Atrial Thrombus and Venous Thrombus by 2035?** A: By 2035, Atrial Thrombus is projected to reach $7.56 Billion, and Venous Thrombus is expected to reach $11.62 Billion. **Q: What treatment types are included in the US thrombus treatment market?** A: The treatment types include Medical Therapy, Surgery, and Others. **Q: What were the market valuations for Medical Therapy, Surgery, and Others in 2024?** A: In 2024, Medical Therapy was valued at $3.66 Billion, Surgery at $2.75 Billion, and Others at $2.75 Billion. **Q: What are the projected market valuations for Medical Therapy, Surgery, and Others by 2035?** A: By 2035, Medical Therapy is projected to reach $7.56 Billion, Surgery $5.75 Billion, and Others $5.87 Billion. **Q: Who are the key players in the US thrombus treatment market?** A: Key players include Bayer AG, Bristol-Myers Squibb Company, Johnson & Johnson, Roche Holding AG, Sanofi S.A., AstraZeneca PLC, Pfizer Inc., and Merck & Co., Inc. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-thrombus-treatment-market-13443*